Cryoglobulinemia
8
3
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.5%
1 terminated out of 8 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Registry for Adults With Plasma Cell Disorders (PCD's)
Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis
Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders